Melanoma Diagnostics Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2017 to 2021 and Forecast 2022 to 2028

$ PRICE - $ 3,000.00$ 8,900.00

Melanoma Diagnostics Market by Type of Condition (Superficial Spreading Melanoma, Lentigo Maligna Melanoma, Nodular Melanoma, Acral Lentiginous Melanoma), Type of Test (Dermatoscopy, Optical Coherence Tomography, Multispectral Imaging, Non-invasive Genome Detection, Electrical impedance spectroscopy (EIS), Fiber Diffraction, Tissue Elastography, Thermal Imaging, Positron emission tomography (PET), MRI –Scan, CT-Scan, Sentinel Lymph Node Biopsy), End user (Diagnostic Centers, Hospitals, Ambulatory Surgical Centers) and Geography (North America, Latin America, Europe, Middle East and Africa, Asia Pacific)

 

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail

Report

Description

Melanoma Diagnostics Market size was valued at USD 3.1 billion in 2021 and is expected to reach USD 5.0 billion by 2028, at a CAGR of 7% during the forecast period 2022-2028. Melanoma is the more serious type of cancer that develops in cells of the skin called melanocytes that produce melanin. Melanoma not only affects the skin but it also affects the eyes and rarely, affects internal organs such as the intestine. The exact cause of melanoma is not clearly known, but the exposure of skin to UV radiation or tanning lamps and beds increases the risk of developing melanoma. The Melanoma Diagnostics market is primarily driven by the increase in the number of people suffering from melanoma coupled with the advancements and approvals of new technologies for the diagnosis of melanoma. In addition, the growing number of developments, current pipeline tests and biomarkers and their expected approvals during the forecast period projected to boost the market over the forecast period. Furthermore, increase in government support and R&D activities to fight against cancer coupled with various initiatives by government and non-government organizations expected to bolster the market growth over the forecast period. However, high cost associated with the diagnosis process, regulatory constraints may hinder the growth of the market globally.

Melanoma Diagnostics Market

MARKET SUMMARY
-
7%
  • Study Period– 2022 – 2028
  • Base Year– 2021
  • CAGR– 7%
  • Largest Market– Europe
  • Fastest Growing Market– North-America

Melanoma Diagnostics Market

  • The global melanoma diagnostics market report gives a comprehensive outlook on aquaculture across the globe with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America, and the Middle East, and Africa.
  • The report on the global melanoma diagnostics market gives historical, current, and future market sizes (US$ Bn) on the basis of type condition, type of test, end user and region.
Key Players
  • Pfizer
  • Sanofi S.A
  • Novartis
  • Merck & Co., Inc.
  • Becton, Dickinson & Co.
Melanoma Diagnostics Market

Drivers And Restraints

The upsurge in the global melanoma prevalence rates and pipeline drugs for the treatment of melanoma is projected to boost the market at significant rates over the forecast period. According to World Health Organization (WHO), there is a continuous increase in the global prevalence of melanoma worldwide and estimated to be 132,000 melanoma skin cancers occur every year. Companies in the marketplace are focused on the development of new biomarker assays and tests for the diagnosis of melanoma. Furthermore, companies also focus on collaborations and acquisitions to develop new drug treatments and expand their portfolio in the market. For instance, in January 2018, Skyline Dx INKS entered into a joint development agreement with mayo clinic to develop diagnostic tests for melanoma


North-America got significant share

Melanoma Diagnostics Market

The North America Melanoma Diagnostics market is expected to grow at significant rates due to the high prevalence of the disease in the region. According to the American Cancer Society, the rates of melanoma are rising over the past 30 years and about 91,270 new melanomas will be diagnosed in 2018. In addition, favorable reimbursement policies in the region coupled with the increase in disposable income are expected to boost the market share of the region over the forecast period. Europe Melanoma Diagnostics market is projected to grow at notable rates owing to the factors such as the growing prevalence of melanoma, the presence of key market players in the region, and an increase in R&D towards the development of new treatments for cancer backed with growing government funding. Asia Pacific Melanoma Diagnostics market is projected to have a lucrative growth opportunity due to growing healthcare expenditure by the population and an increase in R&D investments by the companies and government in the region.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Key Developments

  • In January 2014, Michelson diagnostics, UK based medical device company focused on multi beam optical coherence tomography technology and received award of €2.26 million Framework 7 grant to a consortium of seven partners, towards the cost of project targeting malignant with OCT imaging.

Key

Features of the Report

Melanoma Diagnostics Market Segmentation


Location

GEOGRAPHY

Frequently Asked Questions

2021 is the base year and 2028 is the forecast year.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.


Report

Company Profile

  • Abbott Laboratories (U.S)
  • Ariad Pharmaceuticals, Inc. (U.S)
  • Pfizer (U.S)
  • Sanofi S.A (France)
  • Novartis (Switzerland)
  • Merck & Co., Inc. (U.S)
  • Becton, Dickinson & Co. (U.S)
  • Eli Lilly and Co (U.S)
  • Siemens Healthcare Inc. (Germany)
  • F. Hoffman-La Roche Ltd. (Switzerland)
  • GlaxoSmithKline Plc., etc. (UK)
  • AstraZeneca plc  (UK)
  • Bristol-Myers Squibb (U.S)

Description

Melanoma Diagnostics Market size was valued at USD 3.1 billion in 2021 and is expected to reach USD 5.0 billion by 2028, at a CAGR of 7% during the forecast period 2022-2028. Melanoma is the more serious type of cancer that develops in cells of the skin called melanocytes that produce melanin. Melanoma not only affects the skin but it also affects the eyes and rarely, affects internal organs such as the intestine. The exact cause of melanoma is not clearly known, but the exposure of skin to UV radiation or tanning lamps and beds increases the risk of developing melanoma. The Melanoma Diagnostics market is primarily driven by the increase in the number of people suffering from melanoma coupled with the advancements and approvals of new technologies for the diagnosis of melanoma. In addition, the growing number of developments, current pipeline tests and biomarkers and their expected approvals during the forecast period projected to boost the market over the forecast period. Furthermore, increase in government support and R&D activities to fight against cancer coupled with various initiatives by government and non-government organizations expected to bolster the market growth over the forecast period. However, high cost associated with the diagnosis process, regulatory constraints may hinder the growth of the market globally.

ASIA PACIFIC OFFICE

Precision Business Insights, MIG 366, SAI PLAZA, 1st Floor, KPHB Colony, Hyderabad - 500072

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX